Argadin
Also known as: Argadin cyclic pentapeptide, Cyclo(Arg-Pro-Pro-Tyr-Ile)
Source Argadin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Argadin is a naturally‑derived cyclic pentapeptide that inhibits family‑18 chitinases. Discovered in soil‑derived microorganisms, it binds with nanomolar affinity to bacterial chitinase B and also blocks human and fungal chitinases in vitro. Researchers use Argadin as a molecular probe of chitinase function and as a lead scaffold for developing antifungal, insecticidal, or anti‑inflammatory agents.
Mechanism of Action
Argadin occupies the catalytic cleft of family‑18 chitinases, mimicking the natural chitooligosaccharide substrate. Crystallographic data show the peptide backbone and side‑chains forming hydrogen‑bond and van‑der‑Waals contacts with conserved residues (e.g., Trp220, Trp403) in an aromatic hydrophobic pocket. Intramolecular ionic hydrogen bonds within Argadin stabilize a conformation that maximizes dispersion interactions, thereby preventing substrate turnover.
What the Research Shows
High‑resolution crystal structures (PNAS 2002) revealed how Argadin’s cyclic scaffold mimics carbohydrate binding, explaining its superior potency compared with the classic inhibitor allosamidin. A 2005 Chem Biol study demonstrated activity against bacterial, fungal (Aspergillus fumigatus) and human chitinases, highlighting its broad‑species relevance. Computational work (Bioorg Med Chem 2008) quantified a 20 nM K i for bacterial chitinase B, attributing the affinity to enhanced van‑der‑Waals forces. Subsequent reviews (2010, 2012) described total syntheses, in‑situ click‑chemistry approaches, and rational design of analogues. A 2016 molecular‑orbital study emphasized the role of intramolecular hydrogen bonding and aromatic dispersion in stabilising the Argadin–chitinase complex. All data derive from in‑vitro or computational studies; no animal or clinical investigations have been reported.
Reported Benefits
Argadin offers exceptionally high in‑vitro potency (nanomolar K i) and a well‑characterised binding mode, making it a valuable chemical probe for dissecting chitinase biology. Its cyclic peptide scaffold provides a template for designing more drug‑like inhibitors with improved selectivity. The structural insights gained from Argadin complexes have guided the synthesis of novel analogues and support its potential as a lead for antifungal, insecticidal, or anti‑inflammatory drug development.
Limitations of the Evidence
Evidence is confined to biochemical, structural, and computational studies; there are no reports of cellular, animal, or human efficacy. Selectivity among the multiple human chitinase isoforms remains incompletely defined. Synthesis of the cyclic pentapeptide is complex, and pharmacokinetic properties such as stability, absorption, and distribution have not been evaluated. Consequently, its therapeutic relevance remains speculative.
Safety Considerations
No adverse‑effect data are presented in the literature; Argadin has only been examined in vitro. Because chitinases participate in normal physiological processes (e.g., tissue remodeling, immune responses), off‑target inhibition could theoretically disrupt these functions. Until in‑vivo safety profiling is performed, caution is warranted when extrapolating its effects beyond controlled laboratory assays.
How It Is Administered
Argadin is employed exclusively for research purposes, typically dissolved in aqueous buffers for enzyme‑inhibition assays, crystallography, or computational modelling. The compound is chemically synthesised as a cyclic pentapeptide and is not formulated for clinical administration. All reported uses involve in‑vitro or in‑silico experimental systems.
Routes of Administration
Goals & Uses
- Anti-inflammatory researchInflammationLow
- Chitinase inhibition researchBiochemical ToolModerate
- Asthma treatmentRespiratory / InflammationLow
- Drug scaffold developmentMedicinal ChemistryLow
Contraindications
No contraindications recorded yet.
Adverse Effects
- Unknown systemic toxicityGeneralUnknown
Drug Interactions
No drug interactions recorded yet.
Population Constraints
- General populationGeneralAbsolute
Regulatory Status
- European UnionUnapprovedResearch compound only; no EMA regulatory status
- United StatesUnapprovedResearch compound only; not FDA approved or under IND
- United KingdomUnapprovedResearch compound only; no MHRA regulatory status
No regulatory approvals in any jurisdiction. Used as a research tool compound to study chitinase biology and as a scaffold for drug development.
Evidence & Sources
- Journal ArticleLowRao FV, et al.2005-01-01T00:00:00.000000Z
- Journal ArticleLowGouda H, et al.2008-01-01T00:00:00.000000Z
- Journal ArticleLowHouston DR, et al.2002-01-01T00:00:00.000000Z
- Recent development of two chitinase inhibitors, Argifin and Argadin, produced by soil microorganismsJournal ArticleModerateHirose T, Sunazuka T, Omura S2010-01-01T00:00:00.000000Z
- Journal ArticleLowKoseki J, Gouda H, Hirono S2016-01-01T00:00:00.000000Z
- Journal ArticleModerateHirose T2012-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of enzyme does Argadin inhibit?
Argadin selectively inhibits family‑18 chitinases, enzymes that hydrolyse the polysaccharide chitin. It blocks bacterial, fungal, and human chitinases by occupying the active‑site cleft and mimicking the natural substrate.
Has Argadin been tested in animals or humans?
No. All published work to date reports only in‑vitro enzymatic assays, crystal structures, or computational analyses. No animal efficacy, toxicity, or clinical studies have been documented.
Can Argadin be used as a drug for fungal infections?
While its potent inhibition of fungal chitinases suggests therapeutic potential, Argadin remains a research tool. Its pharmacological properties, safety, and efficacy in living organisms have not been established.
How is Argadin produced for laboratory studies?
The peptide is isolated from soil‑derived microorganisms and can be prepared by total chemical synthesis. Researchers typically dissolve the purified cyclic pentapeptide in buffer for biochemical experiments.
What makes Argadin a better inhibitor than allosamidin?
Structural studies show Argadin’s cyclic scaffold provides tighter van‑der‑Waals contacts and more extensive aromatic interactions within the chitinase active site, resulting in an order‑of‑magnitude lower inhibition constant compared with allosamidin.
What is Argadin?
Argadin is a naturally‑derived cyclic pentapeptide that inhibits family‑18 chitinases. Discovered in soil‑derived microorganisms, it binds with nanomolar affinity to bacterial chitinase B and also blocks human and fungal chitinases in vitro. Researchers use Argadin as a molecular probe of chitinase function and as a lead scaffold for developing antifungal, insecticidal, or anti‑inflammatory agents.
What is Argadin used for?
Argadin is educationally associated with: Anti-inflammatory research, Chitinase inhibition research, Asthma treatment, Drug scaffold development. Educational only — not medical advice.
How is Argadin administered?
Recorded routes of administration: In Vitro, Research Use Only.
What are the potential side effects of Argadin?
Reported adverse effects include: Unknown systemic toxicity. This list is not exhaustive — consult a qualified clinician.